ASND News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AS

Mkt Cap

$14.82B

Volume

586.49K

Next Earnings

November 11th

Loading chart

AS

ASNDAscendis Pharma A/S Ordinary Share

ASND

Pay with—

Available Balance0.00

AS

Mkt Cap

$14.91B

Volume

586.49K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

FDA Grants Priority Review to BridgeBio's Dwarfism Drug FilingBridgeBio Pharma announced FDA acceptance of its regulatory filing for infigratinib, an oral drug to treat achondroplasia in children, with priority review and a decision expected by February 4, 2027. The drug demonstrated 2.1 cm/year greater height growth than placebo in Phase III trials. If approved, it would be the first oral therapy for achondroplasia, differentiating it from injectable competitors. BridgeBio also has two other near-term regulatory catalysts (BBP-418 and encaleret) that could diversify its revenue beyond its current marketed product Attruby.Zacks Investment Research · Oct 7, 2026

BioMarin Stops Voxzogo Development for Noonan SyndromeBioMarin Pharmaceutical announced it is discontinuing development of Voxzogo for Noonan syndrome due to study feasibility and treatment landscape concerns, though not due to safety or efficacy issues. Despite this setback, Voxzogo generated $472 million in first-half 2026 sales (up 9% YoY) and is on track to achieve blockbuster status with expected 2026 sales of $1.00-$1.05 billion. The drug faces increasing competition from Ascendis Pharma's Yuviwel and BridgeBio's infigratinib, though BioMarin secured a royalty-bearing settlement with Ascendis.Zacks Investment Research · Sep 16, 2026

Ascendis Announces Planned $400 Million Share Repurchase ProgramAscendis Pharma A/S announced that its Board of Directors has authorized a $400 million share repurchase program. The company will execute purchases through various methods including open market transactions and accelerated share repurchase agreements, with timing and amounts determined by market conditions and share price.GlobeNewswire Inc. · Sep 14, 2026

How BioMarin Turned a Competitive Threat Into a Royalty-Bearing AssetBioMarin settled a patent dispute with Ascendis Pharma over the achondroplasia drug Yuviwel, converting a competitive threat into a royalty stream. Under the agreement, BioMarin will receive 20% royalties on U.S. Yuviwel sales and 18% in the EU, Brazil, and South Korea through May 2030. While this monetizes competition, BioMarin still faces market pressure from Yuviwel and potential future competitors like BridgeBio's infigratinib.Zacks Investment Research · Sep 3, 2026

Big Pharma Has a Case of Merger ManiaThe pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.The Motley Fool · Jun 30, 2026

Why Is Ascendis Pharma Stock Gaining Friday?Ascendis Pharma reported positive five-year results from its PaTH Forward trial for TransCon PTH (YORVIPATH), showing sustained efficacy and safety in treating adult hypoparathyroidism. The therapy demonstrated that 82% of patients met composite response endpoints, with 88% maintaining normal calcium levels and 96% achieving independence from active vitamin D therapy. The drug showed durable kidney benefits and a consistent safety profile with no new safety signals. ASND stock rose 3.60% to $223.37 on the news.Benzinga · Jun 12, 2026

Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026Ascendis Pharma announced it will present clinical trial data from its rare endocrinology programs at ENDO 2026, including two oral presentations and three posters covering hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency. The presentations will showcase long-term safety and efficacy data for TransCon PTH and benefits of TransCon CNP alone and combined with TransCon hGH in children with achondroplasia.GlobeNewswire Inc. · Jun 8, 2026

Ascendis Pharma to List Ordinary Shares Directly on NasdaqAscendis Pharma A/S announced plans to list its ordinary shares directly on Nasdaq effective April 20, 2026, with all outstanding American Depositary Shares (ADSs) to be exchanged on a 1:1 basis for ordinary shares. The company believes the direct listing will broaden global investment access, potentially facilitate inclusion in equity indexes, and enhance institutional ownership and trading liquidity.GlobeNewswire Inc. · Apr 8, 2026

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and OlderThe FDA has granted accelerated approval to YUVIWEL (navepegritide), developed by Ascendis Pharma, as the first and only once-weekly treatment for children aged 2 and older with achondroplasia. The drug provides continuous systemic exposure to CNP over the weekly dosing interval and is expected to be commercially available in early Q2 2026. The approval was based on improved annualized growth velocity data from three randomized clinical trials.GlobeNewswire Inc. · Feb 27, 2026

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026BridgeBio Pharma announced positive Phase 3 trial results for infigratinib in treating achondroplasia (dwarfism) in children, showing superior annualized height velocity compared to placebo. The company plans to submit FDA and regulatory applications in the second half of 2026. The stock surged 6.92% to $78.41, nearing its 52-week high.Benzinga · Feb 12, 2026

to start trading

AS

ASNDAscendis Pharma A/S Ordinary Share

ASND

Pay with—

Available Balance0.00

Your PositionYou don't own any ASND yet.

Related Tickers

Earnings